Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Ebersberg – page 16

1 343 clinical trials in Ebersberg, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ebersberg at a glance
1 343
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 343 trials in Ebersberg

Open in trial search

Study of belantamab mafodotin with drug combination in adults aged 18 years and older with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Obesity+2

Recruiting

Study of the efficacy and safety of Eloralintide in adults with knee osteoarthritis and overweight or obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

A study to evaluate the use of levothyroxine sodium in patients with sudden onset of dizziness caused by inner ear issues.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Levothyroxine Sodium
  • Sponsor:Klinikum Der Universitat Munchen AöR

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ramucirumab
  • Sponsor:AstraZeneca AB

Study to evaluate the safety and effectiveness of inhaled nintedanib in patients with idiopathic pulmonary fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nintedanib
  • Sponsor:Avalyn Pharma Inc.

Endometrial cancer+2

Recruiting

A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Genmab A/S

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Pfizer Inc.

A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

A study of LY4268989 and mirikizumab in adults with moderately to severely active ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Ebersberg

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer treatment, evaluating the effectiveness of combining immunotherapy with conventional chemotherapy approaches.

  • Neoadjuvant Chemotherapy Studies
  • Immunotherapy Integration
  • Event-free Survival Assessment

Research aims to enhance treatment outcomes through targeted therapeutic combinations.

02 Genetic-Based Treatment

Studies examining treatment efficacy in patients with BRCA mutations, specifically targeting high-risk HER2-negative breast cancer cases.

  • Adjuvant Therapy Development
  • Invasive Disease Management
  • Targeted Treatment Approaches

Focused on improving survival rates through genetically-informed treatment strategies.

03 Hormone Receptor Research

Investigation of advanced treatment protocols for HR+/HER2- early breast cancer, combining endocrine therapy with innovative therapeutic agents.

  • Long-term Endocrine Therapy
  • Combination Treatment Protocols
  • Disease-free Survival Studies

Evaluating enhanced treatment strategies for hormone-responsive breast cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.